Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA

SHANGHAI, China and SAN FRANCISCO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
February 04, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies

Phase 1b Study of Niraparib in Combination with MGD013 in Advanced or Metastatic Gastric Cancer in ChinaRegistrational Bridging Study in China of Margetuximab plus Chemotherapy in HER2-Positive...
January 27, 2020 16:30 ET | Source: Zai Lab Limited

Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option

SHANGHAI, China, and SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage...
January 22, 2020 21:43 ET | Source: Zai Lab Limited

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

SHANGHAI, China, and SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage...
January 21, 2020 16:34 ET | Source: Zai Lab Limited

Zai Lab Announces Proposed Public Offering of American Depositary Shares

SHANGHAI, China, and SAN FRANCISCO, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical...
January 14, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Appoints Lonnie Moulder to Board of Directors

SHANGHAI, China and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the...
January 09, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure...
December 27, 2019 07:41 ET | Source: Zai Lab Limited

Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer

ZEJULA is a potential best-in-class PARP inhibitor for ovarian cancer patients due to its compelling clinical data1, once-daily dosing and pharmacokinetic properties ZEJULA is the first approval for...
December 23, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference

SHANGHAI, China and SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today...
December 16, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board

SHANGHAI, China and SAN FRANCISCO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the...